Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$6.51 - $11.47 $237,556 - $418,551
36,491 Added 51.56%
107,267 $736,000
Q1 2024

May 15, 2024

BUY
$8.68 - $17.36 $614,335 - $1.23 Million
70,776 New
70,776 $682,000
Q1 2023

May 15, 2023

SELL
$13.74 - $25.76 $922,077 - $1.73 Million
-67,109 Reduced 23.35%
220,319 $3.03 Million
Q4 2022

Feb 14, 2023

BUY
$15.45 - $26.02 $629,417 - $1.06 Million
40,739 Added 16.51%
287,428 $4.89 Million
Q3 2022

Nov 14, 2022

SELL
$15.42 - $27.01 $93,229 - $163,302
-6,046 Reduced 2.39%
246,689 $5.61 Million
Q2 2022

Aug 15, 2022

BUY
$13.27 - $25.5 $2.58 Million - $4.96 Million
194,679 Added 335.33%
252,735 $4.56 Million
Q1 2022

May 16, 2022

BUY
$13.42 - $29.73 $779,111 - $1.73 Million
58,056 New
58,056 $1.55 Million
Q2 2021

Aug 13, 2021

SELL
$57.98 - $96.6 $1.51 Million - $2.52 Million
-26,046 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$71.56 - $121.23 $1.86 Million - $3.16 Million
26,046 New
26,046 $2 Million
Q1 2020

May 15, 2020

SELL
$31.51 - $73.75 $156,258 - $365,726
-4,959 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$17.25 - $49.51 $85,542 - $245,520
4,959 New
4,959 $189,000

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $200M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.